# US 2023/0416411 A1 · Antibodies binding to cd3 and folr1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0416411 A1
- Document ID: US20230416411A1
- Status: Published application
- Kind: A1
- Application number: 18/066,526
- Filed: 2022-12-15
- Published: 2023-12-28
- Earliest claimed: 2020-06-19
- Assignees: Hoffmann-La Roche Inc.
- Applicants: Hoffmann-La Roche Inc.
- Inventors: Peter BRUENKER; Martina GEIGER; Christian KLEIN; Alexander KNAUPP
- Web page: https://patentgrep.com/patent/US20230416411A1

## CPC

- C07K 16/468: {Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies}
- A61P 35/00: Antineoplastic agents
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 16/30: from tumour cells
- C07K 16/40: against enzymes
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/31: multispecific
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/40: characterized by post-translational modification
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/55: Fab or Fab'
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/64: comprising a combination of variable region and constant region components
- C07K 2317/66: comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
- C07K 2317/70: characterized by effect upon binding to a cell or to an antigen
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention generally relates to bispecific antibodies that bind to CD3 and Folate Receptor 1 (FolR1), e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

## Claims

### Claim 1

A bispecific antibody that binds to CD3 and Folate receptor 1 (FolR1), wherein the bispecific antibody comprises;
(i) a first antigen binding domain capable of specific binding to CD3, comprising a heavy chain variable region (VH) comprising a heavy chain complementary determining region (HCDR) 1 comprising the amino acid sequence of SEQ ID NO: 2, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 3, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 5, and a light chain variable region (VL) comprising a light chain complementarity determining region (LCDR) 1 comprising the amino acid sequence of SEQ ID NO: 8, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 9, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 10, and
(ii) a second antigen binding domain capable of specific binding to FolR1, comprising a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 124, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 125, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 126, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 8, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 9, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 10.

### Claim 2 (depends on 1)

The bispecific antibody of claim 1, wherein the VH of the first antigen binding domain comprises an amino acid sequence that is at least about 95% identical to the amino acid sequence of SEQ ID NO: 7, and/or the VL comprises an amino acid sequence that is at least about 95% identical to the amino acid sequence of SEQ ID NO: 11.

### Claim 3

A bispecific antibody that binds to CD3 and FolR1, wherein the bispecific antibody comprises:
(i) a first antigen binding domain capable of specific binding to CD3, comprising a VH comprising the amino acid sequence of SEQ ID NO: 7 and a VL comprising the amino acid sequence of SEQ ID NO: 11, and
(ii) a second antigen binding domain capable of specific binding to FolR1, comprising a VH comprising the amino acid sequence of SEQ ID NO: 123 and a VL comprising the amino acid sequence of SEQ ID NO: 11.

### Claim 4 (depends on 1)

The bispecific antibody of claim 1, wherein the first antigen binding domain is a Fab molecule and/or wherein the bispecific antibody further comprises an Fc domain composed of a first and a second subunit.

### Claim 5

(canceled)

### Claim 6 (depends on 4)

The bispecific antibody of claim 4, comprising a third antigen binding domain capable of specific binding to FolR1.

### Claim 7 (depends on 6)

The bispecific antibody of claim 6, wherein:
(i) the second and/or the third antigen binding domain is a Fab molecule; and/or
(ii) the first antigen binding domain is a Fab molecule wherein the variable domains VL and VH or the constant domains CL and CH1 of the Fab light chain and the Fab heavy chain are replaced by each other.

### Claim 8

(canceled)

### Claim 9 (depends on 7)

The bispecific antibody of claim 7, wherein the variable domains VL and VH of the Fab light chain and the Fab heavy chain are replaced by each other.

### Claim 10 (depends on 7)

The bispecific antibody of claim 7, wherein the second and the third antigen binding domains are each a conventional Fab molecule.

### Claim 11 (depends on 10)

The bispecific antibody of claim 10, wherein the second and the third antigen binding domains are each a Fab molecule wherein:
in the constant domain CL the amino acid at position 124 is substituted independently by lysine (K), arginine (R), or histidine (H) (numbering according to Kabat) and the amino acid at position 123 is substituted independently by lysine (K), arginine (R), or histidine (H) (numbering according to Kabat), and
in the constant domain CH1 the amino acid at position 147 is substituted independently by glutamic acid (E) or aspartic acid (D) (numbering according to Kabat EU index) and the amino acid at position 213 is substituted independently by glutamic acid (E) or aspartic acid (D) (numbering according to Kabat EU index).

### Claim 12 (depends on 6)

The bispecific antibody of claim 6, wherein the first and the second antigen binding domains are fused to each other.

### Claim 13 (depends on 12)

The bispecific antibody of claim 12, wherein the first and the second antigen binding domains are fused to each other via a peptide linker.

### Claim 14 (depends on 6)

The bispecific antibody of claim 6, wherein the first and the second antigen binding domains are each a Fab molecule and wherein:
(i) the second antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding domain, or
(ii) the first antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second antigen binding domain.

### Claim 15 (depends on 6)

The bispecific antibody of claim 6, wherein the first, the second, and the third antigen binding domains are each a Fab molecule and the bispecific antibody comprises an Fc domain composed of a first and a second subunit; and wherein:
(i) the second antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding domain and the first antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain, or
(ii) the first antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second antigen binding domain and the second antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain; and the third antigen binding domain, where present, is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second subunit of the Fc domain.

### Claim 16 (depends on 6)

The bispecific antibody of claim 6, wherein the Fc domain is an IgG Fc domain and/or a human Fc domain.

### Claim 17 (depends on 6)

The bispecific antibody of claim 6, wherein the Fc domain is an IgG1 Fc domain.

### Claim 18

(canceled)

### Claim 19 (depends on 6)

The bispecific antibody of claim 6, wherein:
(i) the Fc comprises a modification promoting the association of the first and the second subunit of the Fc domain; and/or
(ii) the Fc domain comprises one or more amino acid substitutions that reduces binding to an Fc receptor and/or an effector function.

### Claim 20

(canceled)

### Claim 21 (depends on 6)

The bispecific antibody of claim 6, wherein the second and the third antigen binding domains each comprises a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 124, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 125, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 126, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 8, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 9, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 10.

### Claim 22 (depends on 6)

The bispecific antibody of claim 6, wherein the second and the third antigen binding domains each comprises a VH comprising an amino acid sequence that is at least about 95% identical to the amino acid sequence of SEQ ID NO: 123, and/or a VL comprising an amino acid sequence that is at least about 95% identical to the amino acid sequence of SEQ ID NO: 11.

### Claim 23 (depends on 21)

An isolated polynucleotide encoding the bispecific antibody of claim 21.

### Claim 24 (depends on 22)

An isolated polynucleotide encoding the bispecific antibody of claim 22.

### Claim 25 (depends on 23)

A host cell comprising the isolated polynucleotide of claim 23.

### Claim 26 (depends on 24)

A host cell comprising the isolated polynucleotide of claim 24.

### Claim 27 (depends on 25)

A method of producing a bispecific antibody that binds to CD3 and FolR1, comprising culturing the host cell of claim 25 under conditions suitable for the expression of the bispecific antibody.

### Claim 28 (depends on 26)

A method of producing a bispecific antibody that binds to CD3 and FolR1, comprising culturing the host cell of claim 26 under conditions suitable for the expression of the bispecific antibody.

### Claim 29 (depends on 21)

A pharmaceutical composition comprising the bispecific antibody of claim 21.

### Claim 30 (depends on 22)

A pharmaceutical composition comprising the bispecific antibody of claim 22.

### Claim 31 (depends on 1)

A method of treating a disease in an individual comprising administering to the subject the bispecific antibody of claim 1.

### Claim 32 (depends on 21)

A method of treating a disease in an individual comprising administering to the subject the bispecific antibody of claim 21.

### Claim 33 (depends on 22)

A method of treating a disease in an individual comprising administering to the subject the bispecific antibody of claim 22.

### Claim 34 (depends on 31)

The method of claim 31, wherein the disease is cancer.

### Claim 35 (depends on 32)

The method of claim 32, wherein the disease is cancer.

### Claim 36 (depends on 33)

The method of claim 33, wherein the disease is cancer.

### Claim 37

A bispecific antibody comprising:
(i) a first antigen binding domain capable of specific binding to CD3, comprising a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO: 2, an HCDR 2 comprising the amino acid sequence of SEQ ID NO: 3, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO: 5, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO: 8, an LCDR 2 comprising the amino acid sequence of SEQ ID NO: 9, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO: 10,
(ii) a second antigen binding domain capable of specific binding to FolR1, and
(iii) a third antigen binding domain capable of specific binding to FolR1, wherein the second and the third antigen binding domains each comprise a VH comprising a HCDR 1 of SEQ ID NO: 124, a HCDR 2 of SEQ ID NO: 125, and a HCDR 3 of SEQ ID NO: 126, and a VL comprising a LCDR 1 of SEQ ID NO: 8, a LCDR 2 of SEQ ID NO: 9 and a LCDR 3 of SEQ ID NO: 10;
wherein the first, second, and third antigen binding domains are each a Fab molecule, wherein the second and third are each a conventional Fab molecule;
wherein in the first antigen binding domain the variable domains VL and VH of the Fab light chain and the Fab heavy chain are replaced by each other;
wherein in each of the second and the third antigen binding domains:
(a) in the constant domain CL, the amino acid at position 124 is substituted independently by lysine (K), arginine (R), or histidine (H) (numbering according to Kabat) and the amino acid at position 123 is substituted independently by lysine (K), arginine (R), or histidine (H) (numbering according to Kabat), and
(b) in the constant domain CH1 the amino acid at position 147 is substituted independently by glutamic acid (E), or aspartic acid (D) (numbering according to Kabat EU index) and the amino acid at position 213 is substituted independently by glutamic acid (E), or aspartic acid (D) (numbering according to Kabat EU index);
wherein:
(a) the second antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding domain and the first antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain, or
(b) the first antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second antigen binding domain and the second antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain; and the third antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second subunit of the Fc domain,
wherein the bispecific antibody comprises an Fc domain composed of a first and a second subunit; and
wherein the Fc domain is an IgG comprising a modification promoting the association of the first and the second subunit of the Fc domain and further comprising one or more amino acid substitutions that reduces binding to an Fc receptor and/or reduces an effector function.

### Claim 38 (depends on 37)

The bispecific antibody of claim 37, wherein the VH of the first antigen binding domain comprises an amino acid sequence that is at least about 95% identical to the amino acid sequence of SEQ ID NO: 7, the VL comprises an amino acid sequence that is at least about 95% identical to the amino acid sequence of SEQ ID NO: 11 and the second and the third antigen binding domains each comprise a VH comprising an amino acid sequence that is at least about 95% identical to the amino acid sequence of SEQ ID NO: 123, and a VL comprising an amino acid sequence that is at least about 95% identical to the amino acid sequence of SEQ ID NO: 11.

### Claim 39 (depends on 37)

The bispecific antibody of claim 37, wherein the Fc domain is an IgG1.

### Claim 40 (depends on 37)

The bispecific antibody of claim 37, wherein the Fc domain is a human Fc domain.

### Claim 41 (depends on 37)

An isolated polynucleotide encoding the bispecific antibody of claim 37.

### Claim 42 (depends on 41)

A host cell comprising the isolated polynucleotide of claim 41.

### Claim 43 (depends on 42)

A method of producing a bispecific antibody that binds to CD3 and FolR1, comprising culturing the host cell of claim 42 under conditions suitable for the expression of the bispecific antibody.

### Claim 44 (depends on 37)

A pharmaceutical composition comprising the bispecific antibody of claim 37.

### Claim 45 (depends on 37)

A method of treating a disease in an individual comprising administering to the subject the bispecific antibody of claim 37.

### Claim 46 (depends on 45)

The method of claim 45, wherein the disease is cancer.

### Claim 47 (depends on 27)

The method of claim 27, further comprising recovering the bispecific antibody.

### Claim 48 (depends on 28)

The method of claim 28, further comprising recovering the bispecific antibody.

### Claim 49 (depends on 43)

The method of claim 43, further comprising recovering the bispecific antibody.
